Background. Little is known about the effect of pulmonary arterial hypertension (PAH) specific therapy on pulmonary hemodynamics and exercise capacity in patients with portopulmonary hypertension (PoPH) because such patients are usually excluded from randomized clinical trials (RCT) of such therapy. Methods. We searched PUBMED using the terms (Therapy/Broad (filter)) AND (portopulmonary hypertension). We included studies that met the following criteria: =5 patients, AND PoPH confirmed by right heart catheterization (RHC), AND follow- up RHC data, AND/OR baseline and follow-up 6MWD available. Results. 12 studiesmet our inclusion criteria. None was a RCT. The baselinemPAP was 48.6 +/- 4.4mmHg, cardiac output (CO) 5.6 +/- 0.9 L/min, and pulmonary vascular resistance (PVR) 668.6 +/- 219.1 dynes. sec/cm(5). The baseline 6MWD was 348.2 +/- 35.6 meters. The use of PAH specific therapy improved mPAP by 7.54mmHg (95% CI 10.2 to 4.9), CO by 1.77 L/min (95% CI 1.1 to 2.4), and PVR by 253 dynes. sec/cm(5) (95% CI 291.4 to 214.6) (n =135) and 6MWD by 61.8 meters (95% CI 47.5 to 76) (n =122). Conclusions. The use of PAH specific therapy in PoPH results in significant improvement in both pulmonary hemodynamics and 6MWD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据